scholarly journals Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients

2021 ◽  
pp. 1-17
Author(s):  
Narges Karimi ◽  
◽  
Reza Boostani ◽  
Farzad Fatehi ◽  
Akram Panahi ◽  
...  
Keyword(s):  
Neuromuscular Disorder ◽  
Nerve Conduction Studies ◽  
Guillain Barre Syndrome ◽  
Upper Respiratory Tract ◽  
Cerebrospinal Fluid Analysis ◽  
Acute Inflammatory Demyelinating Polyneuropathy ◽  
Fluid Analysis ◽  
Guillain Barré Syndrome ◽  
Upper Respiratory ◽  
Guillain Barré

Background: Guillain-Barre syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection. Several studies reported GBS associated with coronavirus-2019 (COVID-19) infection. In this study, we describe nine GBS patients following the COVID-19 vaccine. Methods: In this study, nine patients introduce from six referral centers of neuromuscular disorder in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients administrated the Sinopharm, and two patients received the AstraZeneca vaccine. All patients were diagnosed with GBS, including nerve conduction studies and/or cerebrospinal fluid analysis. Results: The median age of the patients was 54.22 years (range, 26-87 years), and seven patients were male. The patients were treated with intravenous immunoglobulin (IVIg) or plasma exchange (PLEX). All patients were discharged with some improvement. Conclusion: The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS in the general population, this association may be coincidental. Therefore, more studies are needed to investigate a causal relationship.

scholarly journals Guillain-Barré syndrome associated with COVID-19 disease

2020 ◽  
Vol 13 (9) ◽  
pp. e237215 ◽  
Author(s):  
Sindhuja Korem ◽  
Haresh Gandhi ◽  
Decerie Baculi Dayag
Keyword(s):  
Cerebrospinal Fluid ◽  
Clinical Course ◽  
Clinical Manifestations ◽  
Guillain Barre Syndrome ◽  
Upper Respiratory Tract ◽  
Cerebrospinal Fluid Analysis ◽  
Fluid Analysis ◽  
Guillain Barré Syndrome ◽  
Upper Respiratory ◽  
Guillain Barré

Clinical manifestations of COVID-19 are known to be variable with growing evidence of nervous system involvement. In this case report, we describe the symptoms of a patient infected with SARS-CoV-2 whose clinical course was complicated with Guillain-Barré syndrome (GBS). We present a case of a 58-year-old woman who was initially diagnosed with COVID-19 pneumonia due to symptoms of fever and cough. Two weeks later, after the resolution of upper respiratory tract symptoms, she developed symmetric ascending quadriparesis and paresthesias. The diagnosis of GBS was made through cerebrospinal fluid analysis and she was successfully treated with intravenous immunoglobulin administration.

scholarly journals A case of a recurrent GBS

2017 ◽  
Vol 5 (2) ◽  
pp. 135-138
Author(s):  
Md Mahabub Morshed ◽  
AKM Ferdous Rahman ◽  
Syed Tariq Reza ◽  
Muhammad Asaduzzaman ◽  
Mohammad Selim ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Past History ◽  
Complete Recovery ◽  
Guillain Barre Syndrome ◽  
Respiratory Compromise ◽  
Cerebrospinal Fluid Analysis ◽  
Fluid Analysis ◽  
Guillain Barré Syndrome ◽  
History Of ◽  
Guillain Barré

Background: Guillain-Barré syndrome is an acquired polyradiculo-neuropathy, often preceded by an antecedent event. It is a monophasic disease but a recurrence rate of 1–6 % is documented in a subset group of patients.Case presentation: Thirty-five-years-old female with past history of near complete recovery following Guillain-Barré syndrome 17 years back presented with acute, ascending symmetrical flaccid quadriparasis extending to bulbar muscles and respiratory compromise needing mechanical ventilation. Nerve conduction study revealed AMAN variant of Guillain-Barré syndrome. Cerebrospinal fluid analysis done after 1 weeks during recurrent episode revealed albuminocytologic dissociation. She was treated with intravenous immunoglobulin resulting in a remarkable recovery.Conclusion: Recurrence of Guillain-Barré syndrome can occur in a subset of patients with Guillain-Barré syndrome even after many years of asymptomatic period. Most patients with recurrent GBS respond favourably to treatment with plasmapheresis or IVIG.Bangladesh Crit Care J September 2017; 5(2): 135-138

P-PN024. The profile of cerebrospinal fluid analysis in patients with Guillain-Barré Syndrome

2021 ◽  
Vol 132 (8) ◽  
pp. e113
Author(s):  
Wikan Pambudi Nuroso ◽  
Indarwati Setyaningsih ◽  
Kusumo Dananjoyo ◽  
Indra Sari Kusuma Harahap
Keyword(s):  
Cerebrospinal Fluid ◽  
Guillain Barre Syndrome ◽  
Cerebrospinal Fluid Analysis ◽  
Fluid Analysis ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Guillain-Barre Syndrome with Covid-19 Infection

2021 ◽  
Vol 10 (28) ◽  
pp. 2139-2141
Author(s):  
Savita Bansiram Pohekar ◽  
Amruta Shalikram Kothe
Keyword(s):  
Epstein Barr Virus ◽  
Guillain Barre Syndrome ◽  
Cerebrospinal Fluid Analysis ◽  
Barr Virus ◽  
Fluid Analysis ◽  
Breathing Disorders ◽  
Guillain Barré Syndrome ◽  
Epstein Barr ◽  
Guillain Barré ◽  
Muscle Reflexes

COVID-19 from Wuhan, China has spread easily all over the world. Most of the COVID-19 infected patients have fever and breathing disorders. Here, we report a case of Guillain-Barre syndrome (GBS) with a COVID-19 infection. GBS is a very rare disease with corona virus infection. It is really hard to diagnose. In this state the limbs of the patient are slowly weakened. The condition worsens daily with weakness of the limbs. The Guillain-Barre syndrome is a complex and acute or chronic neurological condition. Campylobacter jejuni and other viruses, including cytomegalovirus and Epstein Barr Virus, are causing this condition.1 It is a disorder that is progressive, symmetric, proximate, distal, and characterised by weakness. Muscle reflexes are reduced to absent. Aetiology is unclear, Death is uncommon. The diagnosis of GBS can be made by cerebrospinal fluid analysis and nerve conduction studies.2 We present a case of Guillain-Barre syndrome with COVID-19 infection, who presented to the emergency Outpatient department with complaints of weakness against his bilateral upper and lower limb.

scholarly journals Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1

2021 ◽  
Vol 14 (4) ◽  
pp. e242956
Author(s):  
Shreena Umit Patel ◽  
Ruhaid Khurram ◽  
Anjali Lakhani ◽  
Bernadine Quirk
Keyword(s):  
Interesting Case ◽  
Guillain Barre Syndrome ◽  
Prevention Strategies ◽  
Cerebrospinal Fluid Analysis ◽  
Fluid Analysis ◽  
Main Emphasis ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Whole Spine ◽  
The Brain

Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1, presented to hospital with a rapidly progressive ascending muscle weakness and back pain in the absence of any other triggers. He also had a negative COVID-19 swab during admission. A diagnosis of Guillain-Barre syndrome was confirmed by correlating the clinical features with cerebrospinal fluid analysis, nerve conduction studies and MRI of the brain and whole spine. The patient received treatment with 5 days of intravenous immunoglobulin and did not require any respiratory support. He was also regularly reviewed by a multidisciplinary team consisting of neurologists, speech and language therapists, and physiotherapists and is on the course to a recovery.

scholarly journals Intravenous immunoglobulin in COVID-19 associated Guillain–Barré syndrome in pregnancy

2021 ◽  
Vol 14 (5) ◽  
pp. e242365
Author(s):  
Jao Jarro Garcia ◽  
Christian Wilson Turalde ◽  
Marjorie Anne Bagnas ◽  
Veeda Michelle Anlacan
Keyword(s):  
Intravenous Immunoglobulin ◽  
Supportive Therapy ◽  
Pregnant Patient ◽  
Present Knowledge ◽  
Guillain Barre Syndrome ◽  
Upper Respiratory Tract ◽  
Guillain Barré Syndrome ◽  
History Of ◽  
Upper Respiratory ◽  
Guillain Barré

The COVID-19 pandemic has led to a rise in cases of Guillain-Barré syndrome (GBS). This autoimmune sequela is a manifestation of the neurotropism potential of the virus. At present, knowledge regarding the pathophysiology, clinical features, management and outcomes of the condition is still evolving. This paper presents the case of a 22-year-old pregnant patient who came in with a history of upper respiratory tract symptoms followed by acroparaesthesia and progressive ascending weakness. She was confirmed to have COVID-19 and GBS and was subsequently managed with intravenous immunoglobulin (IVIg) followed by supportive therapy. To the authors’ knowledge and based on their literature search, this is the first reported case of GBS in a COVID-19 confirmed pregnant patient who received IVIg.

scholarly journals A CRITICAL REVIEW ON GUILLAIN BARRE SYNDROME (ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY- AIDP) AND THEIR MANAGEMENT

2020 ◽  
pp. 64-68
Author(s):  
Sahu Abhilasha ◽  
Vyas O.P
Keyword(s):  
Nervous System ◽  
Respiratory Muscles ◽  
Nerve Conduction Studies ◽  
The Body ◽  
Guillain Barre Syndrome ◽  
Acute Inflammatory Demyelinating Polyneuropathy ◽  
Guillain Barré Syndrome ◽  
Life Threatening ◽  
Life Threatening Complication ◽  
Guillain Barré

Guillain- Barre Syndrome is serious health problem, that occurs when the body`s defence system mistakenly attacks parts of the nervous system. In about 50% of people with these syndrome symptoms begin about 5 days to 3 weeks after a mild infection symptoms include weakness and pin and needle sensation or loss of sensation. It is form of polyneuropathy that cause one episode of increasing muscle weakness. Weakness is more prominent than abnormal sensation reflex. Usually weakness begins both legs and moves up the body. In GBS, the body`s immune system attacks the myelin sheath which surround the axon of many nerves and enable nerve impulses to travel quickly. It may lead to life threatening complication in particular if respiratory muscles are affected or if the autonomic nervous system is involved. Worldwide, the annual incidence is about 0.6- 4.0 occurrences per 1,00,000 people. Electromyography and nerve conduction studies can help confirm the diagnosis. Plasmapheresis or immunoglobulin given intravenously may speed recovery. GBS as such is not correlated with any disease which is described in Ayurveda but pathology of GBS is Vata dominating disorder along with association of Pitta and Kapha dosha. As a precipitating factor produced functions of GI biofire plays an important role by producing Ama like reactive species in genesis of this disease. So at the management of GBS through Ayurveda anti-Vata and anti-Ama measures kept in mind while prescribing the drug.

scholarly journals COVID-19 and Guillain-Barre Syndrome - a Case report

2020 ◽  
Author(s):  
Amira Sidig ◽  
Khabab Abbasher ◽  
Mutaz F. Digna ◽  
Mohamed Elsayed ◽  
Hussien Abbasher ◽  
...  
Keyword(s):  
Brain Mri ◽  
Guillain Barre Syndrome ◽  
Upper Respiratory Tract ◽  
Limb Weakness ◽  
Guillain Barré Syndrome ◽  
Progressive Respiratory Failure ◽  
Chest X Ray ◽  
Upper Respiratory ◽  
Guillain Barré ◽  
Chest Ct Scan

Abstract Coronaviruses are a family of related viruses that cause diseases in mammals and avians. Guillain-Barre syndrome is a rare disorder in which the body's immune system attacks peripheral nerves.The case:A 65 years old Sudanese male with no diabetes mellitus or hypertension present to the clinic; On examination, he has upper and lower limb weakness (quadriplegia). The condition was preceded by upper respiratory tract infection. Chest X-ray showed features of pneumonia Chest CT scan showed multiple bilateral ground-glass opacities and consolidation typical of COVID-19 pneumonia. Brain MRI was normal. The COVID-19 nasal swab test was positive. Nerve conduction study showed evidence of polyradiculopathies with dominant demyelination supporting the diagnosis of Guillain-Barre syndrome. The patients died after seven days; because of progressive respiratory failure.

scholarly journals A Case of Acute Motor Sensory Axonal Neuropathy: A Variant of Guillain-Barré Syndrome, with Possible Syndrome of Irreversible Lithium-Effectuated Neurotoxicity

2020 ◽  
Vol 2020 ◽  
pp. 1-4 ◽  
Author(s):  
David Y. Liu ◽  
Jessica R. Hollenbach ◽  
Jason A. Gregorin ◽  
Jonathan H. Wynbrandt
Keyword(s):  
Prolonged Mechanical Ventilation ◽  
Axonal Neuropathy ◽  
Guillain Barre Syndrome ◽  
Respiratory Compromise ◽  
Term Care ◽  
Fluid Analysis ◽  
Guillain Barré Syndrome ◽  
Immune Globulins ◽  
Prolonged Recovery ◽  
Guillain Barré

Acute Motor Sensory Axonal Neuropathy (AMSAN) is a rare and severe variant of Guillain-Barré syndrome (GBS) that has a prolonged recovery course. GBS is often suspected due to ascending muscle weakness, sensation difficulties, respiratory compromise, and antecedent diarrhea. The diagnosis of GBS is supported by cerebrospinal fluid analysis showing albuminocytologic dissociation. Electromyogram and nerve conduction study confirm the diagnosis and allow for further classification by variant. Treatment involves either IV immune globulins or plasmapheresis, and patients typically recover. However, depending on the variant and severity, patients may ultimately require prolonged mechanical ventilation with tracheostomy. In these cases, they may continue to have persistent muscle and sensation abnormalities requiring long-term care. We present a unique case of a 38-year-old female patient with decade-long use of lithium for bipolar disorder that presented with acute lithium toxicity. Though she was ultimately diagnosed with AMSAN, the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) may have also contributed to her persistent neurological sequelae.

SERIAL NERVE CONDUCTION STUDIES IN A GUILLAIN-BARRÉ SYNDROME VARIANT: THE EVOLUTION OF DEMYELINATING CHANGES

2015 ◽  
Vol 86 (11) ◽  
pp. e4.158-e4
Author(s):  
Catherine Morgan ◽  
Benjamin Wakerley ◽  
Geraint Fuller
Keyword(s):  
Nerve Conduction ◽  
Case Series ◽  
Pathological Process ◽  
Nerve Conduction Studies ◽  
Guillain Barre Syndrome ◽  
Facial Weakness ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Underlying Pathology ◽  
Serial Assessments

Guillain Barré syndrome (GBS) varies both in terms of clinical phenotype and underlying pathology. Serial assessments allow greater understanding of the pathophysiology. The evolution of neurophysiological changes is particularly helpful in distinguishing between demyelination and reversible axonal conduction failure.Bilateral facial weakness with distal paraesthesias is a rare subtype of GBS. In the largest case series 64% had abnormalities in motor and 27% in sensory conduction on single neurophysiological assessments; this was interpreted as a demyelinating neuropathy.We report an 18-year-old male with bilateral lower motor neurone facial weakness preceded by distal paraesthesias following a ‘flu-like illness. Examination of power and sensation was normal. Deep tendon reflexes were present. Cerebrospinal fluid showed albuminocytologic dissociation. By 6 weeks his facial weakness had almost completely resolved without treatment.Serial nerve conduction studies were performed. The first study (day 4) found prolonged distal motor latency and delayed F waves in posterior tibial and common peroneal nerves; normal sensory studies. Second study (day 18) found distal motor latencies and F waves had increased in upper and lower limb nerves. Third study (day 60) found improvement but abnormalities remained with changes similar to the first study.The neurophysiological changes became more marked while he improved clinically. These serial studies confirmed the primary pathological process of this GBS variant to be demyelination.

Sign in / Sign up

Export Citation Format

Share Document